Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2025

Cho Byoung Chul, Hayashi Hidetoshi, Lee Jong-Seok, Lee Se-Hoon, Danchaivijitr Pongwut, Cheng Ying, Liu Baogang, Alip Adlinda, Xiong Hailin, How Soon Hin, Chang Gee-Chen, Yang James Chih-Hsin, Yoshioka Hiroshige, Nahit Şendur Mehmet Ali, Prabhash Kumar, Azuma Koichi, Lee Yun-Gyoo, Lin Chien-Chung, Matsumoto Shingo, Sunpaweravong Patrapim, Xia Yichuan, Martinez Melissa, Bauml Joshua M, Sethi Seema, Lu Shun

Abstract excerpt

INTRODUCTION: The incidence of epidermal growth factor receptor (EGFR) mutations is higher among Asian patients with advanced non-small cell lung cancer than the general advanced non-small cell lung cancer population. We evaluated the efficacy and safety of amivantamab in combination with lazertinib versus osimertinib in Asian participants from the phase 3 MARIPOSA study who had treatment-naïve advanced non-small...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Aniline Compounds

ErbB Receptors

Male

Acrylamides

Middle Aged

Aged

Mutation

Antineoplastic Combined Chemotherapy Protocols

Adult

Treatment Outcome

Asian People

Indoles

Pyrimidines

Source

Identifiers

PMID: 40300278
DOI: 10.1016/j.lungcan.2025.108496

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.PMID 40300278Read ↗

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.Semantic proximity Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.Semantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.Semantic proximity Read ↗

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.Semantic proximity Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.Semantic proximity Read ↗

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read ↗

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Semantic proximity Read ↗

The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.